{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:20:21Z","timestamp":1776871221054,"version":"3.51.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12185-018-2428-0","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T06:47:58Z","timestamp":1519714078000},"page":"681-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan"],"prefix":"10.1007","volume":"107","author":[{"given":"Ayako","family":"Kamiunten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Shide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Kubuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousuke","family":"Marutsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Akizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruko","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"2428_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"2428_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"2428_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"2428_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"2428_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"2428_CR6","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123\u201333.","journal-title":"Blood"},{"key":"2428_CR7","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379\u201390.","journal-title":"N Engl J Med"},{"key":"2428_CR8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391\u2013405.","journal-title":"N Engl J Med."},{"key":"2428_CR9","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med."},{"key":"2428_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12185-017-2246-9","volume":"105","author":"M Imai","year":"2017","unstructured":"Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol. 2017;105:743\u20137.","journal-title":"Int J Hematol"},{"key":"2428_CR11","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995\u20133001.","journal-title":"J Clin Oncol."},{"key":"2428_CR12","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224\u201332.","journal-title":"J Clin Oncol"},{"key":"2428_CR13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120:1197\u2013201.","journal-title":"Blood"},{"key":"2428_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12185-016-2105-0","volume":"105","author":"AM Yesilova","year":"2017","unstructured":"Yesilova AM, Yavuzer S, Yavuzer H, Cengiz M, Toprak ID, Hanedar E, et al. Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. Int J Hematol. 2017;105:70\u20138.","journal-title":"Int J Hematol"},{"key":"2428_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.beha.2005.07.007","volume":"19","author":"T Barbui","year":"2006","unstructured":"Barbui T, Finazzi G. Evidence-based management of polycythemia vera. Best Pract Res Clin Haematol. 2006;19:483\u201393.","journal-title":"Best Pract Res Clin Haematol."},{"key":"2428_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","unstructured":"Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20\u00a0years. Ann Intern Med. 1995;123:656\u201364.","journal-title":"Ann Intern Med."},{"key":"2428_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275\u201390.","journal-title":"Br J Haematol"},{"key":"2428_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3324\/haematol.12604","volume":"93","author":"R Landolfi","year":"2008","unstructured":"Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:331\u20135.","journal-title":"Haematologica"},{"key":"2428_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ajh.23895","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90:162\u201373.","journal-title":"Am J Hematol"},{"key":"2428_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22\u201333.","journal-title":"N Engl J Med"},{"key":"2428_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","volume":"8","author":"S Cortelazzo","year":"1990","unstructured":"Cortelazzo S, Viero P, Finazzi G, D\u2019Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556\u201362.","journal-title":"J Clin Oncol"},{"key":"2428_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/sj.leu.2401270","volume":"13","author":"C Besses","year":"1999","unstructured":"Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150\u20134.","journal-title":"Leukemia"},{"key":"2428_CR23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761\u201370.","journal-title":"J Clin Oncol"},{"key":"2428_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12185-017-2330-1","volume":"106","author":"N Usui","year":"2017","unstructured":"Usui N. JSH guideline for tumors of hematopoietic and lymphoid tissues\u2014lukemia: 4. Chronic myelogenous leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2017;106:591\u2013611.","journal-title":"Int J Hematol"},{"key":"2428_CR25","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128\u201333 (quiz 252).","journal-title":"Blood."},{"issue":"Suppl 1","key":"2428_CR26","first-page":"87","volume":"22","author":"TC Pearson","year":"1996","unstructured":"Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma. 1996;22(Suppl 1):87\u201393.","journal-title":"Leuk Lymphoma"},{"key":"2428_CR27","unstructured":"Swerdlow, S.H. et al. (ed.). WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008, p 40\u201350."},{"key":"2428_CR28","unstructured":"Jaffe, E.S. et al. (ed.). World Health Organization classification of tumors. Lyon: IARC Press; 2001, pp 230\u2013235."},{"key":"2428_CR29","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.","journal-title":"Blood Cancer J."},{"key":"2428_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12185-014-1567-1","volume":"99","author":"Y Edahiro","year":"2014","unstructured":"Edahiro Y, Morishita S, Takahashi K, Hironaka Y, Yahata Y, Sunami Y, et al. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol. 2014;99:625\u201334.","journal-title":"Int J Hematol"},{"key":"2428_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.leukres.2015.11.002","volume":"40","author":"M Okabe","year":"2016","unstructured":"Okabe M, Yamaguchi H, Usuki K, Kobayashi Y, Kawata E, Kuroda J, et al. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L\/K mutations. Leuk Res. 2016;40:68\u201376.","journal-title":"Leuk Res"},{"key":"2428_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459\u201368.","journal-title":"N Engl J Med"},{"key":"2428_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1532\/IJH97.06009","volume":"83","author":"K Dan","year":"2006","unstructured":"Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006;83:443\u20139.","journal-title":"Int J Hematol"},{"key":"2428_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","volume":"136","author":"M Nisio Di","year":"2007","unstructured":"Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136:249\u201359.","journal-title":"Br J Haematol"},{"key":"2428_CR35","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121:1720\u20138.","journal-title":"Blood"},{"key":"2428_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3324\/haematol.2017.174672","volume":"103","author":"G Birgegard","year":"2018","unstructured":"Birgegard G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the EXELS study. Haematologica. 2018;103:51\u201360.","journal-title":"Haematologica"},{"key":"2428_CR37","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.","journal-title":"Blood Cancer J."},{"key":"2428_CR38","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/leu.2013.74","volume":"27","author":"T Barbui","year":"2013","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early\/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013;27:1953\u20138.","journal-title":"Leukemia"},{"key":"2428_CR39","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"117","author":"J Thiele","year":"2011","unstructured":"Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710\u20138.","journal-title":"Blood"},{"key":"2428_CR40","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"2428_CR41","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ajh.23685","volume":"89","author":"M Montanaro","year":"2014","unstructured":"Montanaro M, Latagliata R, Cedrone M, Spadea A, Rago A, Di Giandomenico J, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. Am J Hematol. 2014;89:542\u20136.","journal-title":"Am J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2428-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:21:59Z","timestamp":1551313319000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2428-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["2428"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2428-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]},"assertion":[{"value":"5 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We have no financial relationships to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}